新证据:甲胺不适合作为乳腺癌的常规辅助剂:一种药物向的门德尔随机化分析
Jing-Xuan Xu1,2, Qi-Long Zhu3, Yu-Miao Bi4
1Department of General Surgery, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.
BMC cancer
|June 6, 2024
概括
梅特福林似乎不会因果性地增加整体乳腺癌 (BC) 风险,尽管它已知对2型糖尿病的影响. 然而,它可能会增加雌激素受体阳性和HER2阴性乳腺癌亚型的风险.
科学领域:
- 药物基因组学 药物基因组学
- 在瘤学瘤学.
- 代谢疾病 代谢疾病
背景情况:
- 甲胺是一种广泛用于治疗2型糖尿病的药物.
- 它在乳腺癌 (BC) 风险中的潜在作用受到争论.
- 基因研究可以阐明药物标和疾病风险之间的因果关系.
研究的目的:
- 通过使用遗传数据,调查甲胺的主要点与乳腺癌风险之间的潜在因果关系.
- 评估甲福明标和整体BC风险以及特定亚型之间的关联.
主要方法:
- 利用孟德尔随机化 (MR) 与来自IEU OpenGWAS和FinnGen. 的全基因组关联研究 (GWAS) 数据.
- 分析了甲胺标 (PRKAB1,ETFDH,GPD1L) 与乳腺癌风险之间的遗传关联.
- 包括可靠性的灵敏度和类药物测试以及对2型糖尿病的阳性对照分析.
主要成果:
- 在甲福明的主要点和整体乳腺癌风险之间没有发现显著的因果关系.
- 在ETFDH和雌激素受体 (ER) 阳性BC之间观察到因果关系.
- 观察到GPD1L和人类表皮生长因子受体2 (HER2) - 阴性BC之间存在因果关系.
结论:
- 甲胺的主要点PRKAB1与乳腺癌风险没有因果关系.
- 甲胺抑制ETFDH和GPD1L可能会分别增加ER阳性和HER2阴性乳腺癌的风险.
- 没有2型糖尿病的乳腺癌患者不建议使用甲福明作为补充疗法.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K